Coloplast A/S Logo

Coloplast A/S

COLO-B.CO

(2.8)
Stock Price

906,80 DKK

27.58% ROA

30.5% ROE

39.34x PER

Market Cap.

198.159.398.952,00 DKK

113.6% DER

2.42% Yield

18.88% NPM

Coloplast A/S Stock Analysis

Coloplast A/S Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Coloplast A/S Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (69.03%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

4 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (3.919) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (24.39x) suggests it's overvalued, potentially making it an expensive investment.

8 DER

The company has a high debt to equity ratio (341%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Coloplast A/S Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Coloplast A/S Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Coloplast A/S Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Coloplast A/S Revenue
Year Revenue Growth
2002 5.624.000.000
2003 5.669.000.000 0.79%
2004 6.072.349.772 6.64%
2005 6.232.000.000 2.56%
2006 6.709.000.000 7.11%
2007 8.042.000.000 16.58%
2008 8.463.000.000 4.97%
2009 8.820.000.000 4.05%
2010 9.537.000.000 7.52%
2011 10.172.000.000 6.24%
2012 11.023.000.000 7.72%
2013 11.635.000.000 5.26%
2014 12.428.000.000 6.38%
2015 13.909.000.000 10.65%
2016 14.681.000.000 5.26%
2017 15.528.000.000 5.45%
2018 16.449.000.000 5.6%
2019 17.939.000.000 8.31%
2020 18.544.000.000 3.26%
2021 19.426.000.000 4.54%
2022 22.579.000.000 13.96%
2023 24.500.000.000 7.84%
2024 27.540.000.000 11.04%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Coloplast A/S Research and Development Expenses
Year Research and Development Expenses Growth
2002 173.000.000
2003 168.000.000 -2.98%
2004 200.923.338 16.39%
2005 215.000.000 6.55%
2006 97.000.000 -121.65%
2007 135.000.000 28.15%
2008 415.000.000 67.47%
2009 389.000.000 -6.68%
2010 409.000.000 4.89%
2011 415.000.000 1.45%
2012 342.000.000 -21.35%
2013 380.000.000 10%
2014 390.000.000 2.56%
2015 442.000.000 11.76%
2016 509.000.000 13.16%
2017 574.000.000 11.32%
2018 640.000.000 10.31%
2019 692.000.000 7.51%
2020 708.000.000 2.26%
2021 755.000.000 6.23%
2022 866.000.000 12.82%
2023 872.000.000 0.69%
2024 960.000.000 9.17%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Coloplast A/S General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 751.000.000
2003 727.000.000 -3.3%
2004 721.835.695 -0.72%
2005 -1.159.000.000 162.28%
2006 -722.000.000 -60.53%
2007 -809.000.000 10.75%
2008 882.000.000 191.72%
2009 614.000.000 -43.65%
2010 557.000.000 -10.23%
2011 604.000.000 7.78%
2012 622.000.000 2.89%
2013 533.000.000 -16.7%
2014 498.000.000 -7.03%
2015 600.000.000 17%
2016 561.000.000 -6.95%
2017 623.000.000 9.95%
2018 653.000.000 4.59%
2019 757.000.000 13.74%
2020 762.000.000 0.66%
2021 762.000.000 0%
2022 1.005.000.000 24.18%
2023 1.115.000.000 9.87%
2024 1.200.000.000 7.08%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Coloplast A/S EBITDA
Year EBITDA Growth
2002 1.774.000.000
2003 1.486.000.000 -19.38%
2004 1.131.123.977 -31.37%
2005 1.416.000.000 20.12%
2006 1.309.000.000 -8.17%
2007 1.620.000.000 19.2%
2008 1.734.000.000 6.57%
2009 2.005.000.000 13.52%
2010 2.685.000.000 25.33%
2011 3.154.000.000 14.87%
2012 3.797.000.000 16.93%
2013 4.099.000.000 7.37%
2014 4.572.000.000 10.35%
2015 5.001.000.000 8.58%
2016 5.333.000.000 6.23%
2017 5.521.000.000 3.41%
2018 5.558.000.000 0.67%
2019 6.213.000.000 10.54%
2020 6.444.000.000 3.58%
2021 7.233.000.000 10.91%
2022 7.864.000.000 8.02%
2023 7.730.000.000 -1.73%
2024 8.740.000.000 11.56%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Coloplast A/S Gross Profit
Year Gross Profit Growth
2002 3.413.000.000
2003 3.512.000.000 2.82%
2004 3.735.685.767 5.99%
2005 3.789.000.000 1.41%
2006 5.022.000.000 24.55%
2007 6.097.000.000 17.63%
2008 4.998.000.000 -21.99%
2009 5.103.000.000 2.06%
2010 5.844.000.000 12.68%
2011 6.568.000.000 11.02%
2012 7.345.000.000 10.58%
2013 7.866.000.000 6.62%
2014 8.538.000.000 7.87%
2015 9.533.000.000 10.44%
2016 10.032.000.000 4.97%
2017 10.571.000.000 5.1%
2018 11.066.000.000 4.47%
2019 12.153.000.000 8.94%
2020 12.612.000.000 3.64%
2021 13.313.000.000 5.27%
2022 15.529.000.000 14.27%
2023 16.328.000.000 4.89%
2024 18.592.000.000 12.18%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Coloplast A/S Net Profit
Year Net Profit Growth
2002 768.000.000
2003 561.000.000 -36.9%
2004 587.886.803 4.57%
2005 553.000.000 -6.31%
2006 466.000.000 -18.67%
2007 370.000.000 -25.95%
2008 715.000.000 48.25%
2009 883.000.000 19.03%
2010 1.243.000.000 28.96%
2011 1.819.000.000 31.67%
2012 2.194.000.000 17.09%
2013 2.711.000.000 19.07%
2014 2.390.000.000 -13.43%
2015 899.000.000 -165.85%
2016 3.143.000.000 71.4%
2017 3.797.000.000 17.22%
2018 3.845.000.000 1.25%
2019 3.873.000.000 0.72%
2020 4.197.000.000 7.72%
2021 4.825.000.000 13.02%
2022 4.706.000.000 -2.53%
2023 4.783.000.000 1.61%
2024 5.096.000.000 6.14%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Coloplast A/S Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 3
2003 2 -200%
2004 2 0%
2005 2 50%
2006 2 0%
2007 2 -100%
2008 3 66.67%
2009 4 25%
2010 6 20%
2011 9 37.5%
2012 10 20%
2013 13 16.67%
2014 11 -9.09%
2015 4 -175%
2016 15 71.43%
2017 18 17.65%
2018 18 5.56%
2019 18 0%
2020 20 5.26%
2021 23 13.64%
2022 22 0%
2023 22 0%
2024 23 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Coloplast A/S Free Cashflow
Year Free Cashflow Growth
2002 413.000.000
2003 107.000.000 -285.98%
2004 439.054.700 75.63%
2005 894.000.000 50.89%
2006 509.000.000 -75.64%
2007 408.000.000 -24.75%
2008 701.000.000 41.8%
2009 1.413.000.000 50.39%
2010 1.463.000.000 3.42%
2011 1.955.000.000 25.17%
2012 2.311.000.000 15.4%
2013 2.696.000.000 14.28%
2014 2.616.000.000 -3.06%
2015 2.720.000.000 3.82%
2016 2.379.000.000 -14.33%
2017 2.566.000.000 7.29%
2018 3.692.000.000 30.5%
2019 3.721.000.000 0.78%
2020 3.828.000.000 2.8%
2021 3.324.000.000 -15.16%
2022 3.964.000.000 16.15%
2023 2.985.000.000 -32.8%
2024 1.138.000.000 -162.3%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Coloplast A/S Operating Cashflow
Year Operating Cashflow Growth
2002 913.000.000
2003 911.000.000 -0.22%
2004 840.901.377 -8.34%
2005 1.353.000.000 37.85%
2006 966.000.000 -40.06%
2007 1.004.000.000 3.78%
2008 1.324.000.000 24.17%
2009 1.830.000.000 27.65%
2010 1.769.000.000 -3.45%
2011 2.205.000.000 19.77%
2012 2.649.000.000 16.76%
2013 3.136.000.000 15.53%
2014 3.149.000.000 0.41%
2015 3.337.000.000 5.63%
2016 3.028.000.000 -10.2%
2017 3.251.000.000 6.86%
2018 4.361.000.000 25.45%
2019 4.357.000.000 -0.09%
2020 4.759.000.000 8.45%
2021 5.290.000.000 10.04%
2022 5.099.000.000 -3.75%
2023 4.226.000.000 -20.66%
2024 1.490.000.000 -183.62%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Coloplast A/S Capital Expenditure
Year Capital Expenditure Growth
2002 500.000.000
2003 804.000.000 37.81%
2004 401.846.676 -100.08%
2005 459.000.000 12.45%
2006 457.000.000 -0.44%
2007 596.000.000 23.32%
2008 623.000.000 4.33%
2009 417.000.000 -49.4%
2010 306.000.000 -36.27%
2011 250.000.000 -22.4%
2012 338.000.000 26.04%
2013 440.000.000 23.18%
2014 533.000.000 17.45%
2015 617.000.000 13.61%
2016 649.000.000 4.93%
2017 685.000.000 5.26%
2018 669.000.000 -2.39%
2019 636.000.000 -5.19%
2020 931.000.000 31.69%
2021 1.966.000.000 52.64%
2022 1.135.000.000 -73.22%
2023 1.241.000.000 8.54%
2024 352.000.000 -252.56%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Coloplast A/S Equity
Year Equity Growth
2002 1.569.000.000
2003 2.010.000.000 21.94%
2004 2.358.988.820 14.79%
2005 2.514.000.000 6.17%
2006 2.805.000.000 10.37%
2007 2.400.000.000 -16.88%
2008 2.290.000.000 -4.8%
2009 2.850.000.000 19.65%
2010 3.452.000.000 17.44%
2011 4.478.000.000 22.91%
2012 6.042.000.000 25.89%
2013 6.769.000.000 10.74%
2014 6.283.000.000 -7.74%
2015 4.706.000.000 -33.51%
2016 5.068.000.000 7.14%
2017 5.952.000.000 14.85%
2018 6.418.000.000 7.26%
2019 6.913.000.000 7.16%
2020 7.406.000.000 6.66%
2021 8.168.000.000 9.33%
2022 8.292.000.000 1.5%
2023 17.299.000.000 52.07%
2024 16.524.000.000 -4.69%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Coloplast A/S Assets
Year Assets Growth
2002 4.489.000.000
2003 5.360.000.000 16.25%
2004 5.640.736.675 4.98%
2005 5.915.000.000 4.64%
2006 7.982.000.000 25.9%
2007 7.750.000.000 -2.99%
2008 7.981.000.000 2.89%
2009 7.963.000.000 -0.23%
2010 7.771.000.000 -2.47%
2011 9.218.000.000 15.7%
2012 10.176.000.000 9.41%
2013 9.364.000.000 -8.67%
2014 10.379.000.000 9.78%
2015 10.817.000.000 4.05%
2016 11.007.000.000 1.73%
2017 12.050.000.000 8.66%
2018 11.769.000.000 -2.39%
2019 12.732.000.000 7.56%
2020 13.499.000.000 5.68%
2021 15.841.000.000 14.78%
2022 34.956.000.000 54.68%
2023 48.159.000.000 27.42%
2024 48.580.000.000 0.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Coloplast A/S Liabilities
Year Liabilities Growth
2002 2.920.000.000
2003 3.350.000.000 12.84%
2004 3.274.306.249 -2.31%
2005 3.401.000.000 3.73%
2006 5.177.000.000 34.31%
2007 5.350.000.000 3.23%
2008 5.690.000.000 5.98%
2009 5.113.000.000 -11.28%
2010 4.319.000.000 -18.38%
2011 4.740.000.000 8.88%
2012 4.134.000.000 -14.66%
2013 2.595.000.000 -59.31%
2014 4.096.000.000 36.65%
2015 6.111.000.000 32.97%
2016 5.939.000.000 -2.9%
2017 6.098.000.000 2.61%
2018 5.351.000.000 -13.96%
2019 5.819.000.000 8.04%
2020 6.093.000.000 4.5%
2021 7.673.000.000 20.59%
2022 26.664.000.000 71.22%
2023 30.860.000.000 13.6%
2024 32.056.000.000 3.73%

Coloplast A/S Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
117.01
Net Income per Share
22.1
Price to Earning Ratio
39.34x
Price To Sales Ratio
7.53x
POCF Ratio
75.18
PFCF Ratio
150.92
Price to Book Ratio
11.82
EV to Sales
8.24
EV Over EBITDA
26.18
EV to Operating CashFlow
83.42
EV to FreeCashFlow
165.12
Earnings Yield
0.03
FreeCashFlow Yield
0.01
Market Cap
198,16 Bil.
Enterprise Value
216,80 Bil.
Graham Number
191.16
Graham NetNet
-111.39

Income Statement Metrics

Net Income per Share
22.1
Income Quality
0.43
ROE
0.3
Return On Assets
0.1
Return On Capital Employed
0.2
Net Income per EBT
0.79
EBT Per Ebit
0.89
Ebit per Revenue
0.27
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.68
Operating Profit Margin
0.27
Pretax Profit Margin
0.24
Net Profit Margin
0.19

Dividends

Dividend Yield
0.02
Dividend Yield %
2.42
Payout Ratio
0.95
Dividend Per Share
21

Operating Metrics

Operating Cashflow per Share
11.56
Free CashFlow per Share
5.84
Capex to Operating CashFlow
0.49
Capex to Revenue
0.05
Capex to Depreciation
1.04
Return on Invested Capital
0.16
Return on Tangible Assets
0.28
Days Sales Outstanding
79.37
Days Payables Outstanding
50.59
Days of Inventory on Hand
157.08
Receivables Turnover
4.6
Payables Turnover
7.21
Inventory Turnover
2.32
Capex per Share
5.72

Balance Sheet

Cash per Share
3,95
Book Value per Share
73,51
Tangible Book Value per Share
-62.5
Shareholders Equity per Share
73.51
Interest Debt per Share
87.06
Debt to Equity
1.14
Debt to Assets
0.39
Net Debt to EBITDA
2.25
Current Ratio
0.85
Tangible Asset Value
-14,05 Bil.
Net Current Asset Value
-21,42 Bil.
Invested Capital
35182000000
Working Capital
-1,83 Bil.
Intangibles to Total Assets
0.63
Average Receivables
5,64 Bil.
Average Payables
1,21 Bil.
Average Inventory
3619000000
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Coloplast A/S Dividends
Year Dividends Growth
2000 3
2001 4 0%
2002 4 25%
2003 5 20%
2004 6 16.67%
2005 4 -100%
2006 4 25%
2007 9 55.56%
2008 6 -50%
2009 7 14.29%
2010 10 30%
2011 14 28.57%
2012 20 30%
2013 10 -100%
2014 12 16.67%
2015 13 0%
2016 14 7.69%
2017 15 13.33%
2018 16 6.25%
2019 17 5.88%
2020 18 5.56%
2021 19 5.26%
2022 20 5%
2023 21 4.76%
2024 5 -320%

Coloplast A/S Profile

About Coloplast A/S

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

CEO
Mr. Kristian Villumsen
Employee
16.019
Address
Holtedam 1-3
Humlebæk, 3050

Coloplast A/S Executives & BODs

Coloplast A/S Executives & BODs
# Name Age
1 Mr. Thomas Barfod
Senior Controller & Employees Representative Director
70
2 Mr. Paul Marcun
Executive Vice President of Growth
70
3 Mr. Kristian Villumsen
President & Chief Executive Officer
70
4 Ellen Bjurgert
Vice President of Investor Relations
70
5 Dennis Kaysen
Director of Corporate Communications
70
6 Dorthe Ronnau
Senior Vice President of People & Culture
70
7 Mr. Nicolai Buhl Andersen
Executive Vice President of Innovation
70
8 Mr. Anders Lonning-Skovgaard
Executive Vice President & Chief Financial Officer
70
9 Mr. Allan Rasmussen
Executive Vice President of Global Operations
70
10 Mr. Alain Morvan
Senior Vice President of Sales Europe
70

Coloplast A/S Competitors

Novozymes A/S Logo
Novozymes A/S

NZYM-B.CO

(3.5)
DSV A/S Logo
DSV A/S

DSV.CO

(2.0)
GN Store Nord A/S Logo
GN Store Nord A/S

GN.CO

(1.2)
Ambu A/S Logo
Ambu A/S

AMBU-B.CO

(0.5)